Victoza for weight loss: what liraglutide actually does
Quick answer
The creator appears to be using Saxenda (liraglutide 3.0 mg, approved for weight management) but refers to it throughout as Victoza, which is a different liraglutide product approved only for type 2 diabetes at a maximum 1.8 mg dose. She is self-directing her titration from 2.4 mg to 3.0 mg with physician permission, which deviates from the standard weekly step-up schedule outlined in Saxenda's prescribing information. She also reports new injection site bruising at higher doses, a side effect that warrants technique review and prescriber consultation rather than peer input.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @rhondagsigler actually say?
Rhonda shared a weight loss update while on liraglutide (Victoza), noting she'd broken through a stall after dealing with constipation, stress, and poor food choices. She plans to increase her dose from 2.4 mg to "the 3.0 max" and says her doctor lets her decide when to move up. She also flagged worsening stomach bruising at higher doses and asked followers about switching injection sites for better efficacy.
To her credit, she connects the lifestyle basics, protein intake, hydration, bowel regularity, sleep routines, and mental health, to her overall progress. She's not selling anything or making outrageous claims. But a few things she said deserve a closer look, because they're either medically off or could lead viewers in the wrong direction.
Does the science back this up?
The stress-weight connection is real, the injection site efficacy question is more complicated than she suggests, and the dose numbers she's citing don't quite line up with how Victoza actually works.
On stress: cortisol does promote fat storage, particularly visceral fat, and disrupts hunger-regulating hormones like leptin and ghrelin. A 2022 review by Xenaki et al. in Hormones confirmed that chronic psychological stress is associated with weight gain and poorer dietary choices, especially in women. She's right on that one.
On injection sites: a 2021 meta-analysis by Hofman et al. in Diabetes Care found that absorption of subcutaneous GLP-1 medications can vary modestly by site, with the abdomen generally showing the most consistent absorption. Her claim that the thigh is "statistically the least effective spot" has some basis, but the clinical difference is typically small and varies by individual.
On dosing: liraglutide for weight management is sold as Saxenda, not Victoza. Victoza tops out at 1.8 mg for type 2 diabetes. Saxenda goes up to 3.0 mg. Mixing up these two products matters, because they have different approved indications and titration schedules.
What did they get wrong (or right)?
The dose numbers are the clearest problem here. She says she's on "2.4" and going up to "3.0 max." Those are Saxenda doses, not Victoza doses. Victoza's maximum approved dose is 1.8 mg. If she's actually on 2.4 mg of liraglutide, she is on Saxenda, not Victoza, regardless of what she calls it. That's not a nitpick. The two products have different labeling, different approved uses, and different titration protocols. Using the wrong name in a video with 11,800 views could genuinely confuse people about what medication they're on or what doses are appropriate.
The self-directed dosing setup she describes, where her doctor lets her choose when to increase, is not standard practice. Saxenda has a defined titration schedule (0.6 mg weekly increases) specifically to reduce GI side effects. Patient-controlled titration outside that structure isn't supported by the prescribing guidelines and could increase adverse event risk.
What she got right: her instinct to address constipation before increasing dose is actually sound. GI side effects worsen with faster titration. The bruising concern is legitimate and worth raising with her prescriber, not crowdsourcing on TikTok.
What should you actually know?
If you're on liraglutide for weight loss, you are almost certainly on Saxenda, not Victoza. They contain the same molecule but are different products with different approved doses. Victoza is approved for type 2 diabetes at up to 1.8 mg. Saxenda is approved for chronic weight management at up to 3.0 mg. Calling one the other creates real confusion about dosing expectations.
On bruising: injection site bruising with liraglutide tends to worsen if you're reusing the same small area repeatedly, injecting too quickly, or not letting alcohol dry before injecting. It is worth bringing up with your provider, not because it signals danger, but because technique adjustments usually help. Rotating sites within the recommended zones, abdomen, thigh, upper arm, is the standard recommendation.
On patient-controlled titration: some clinicians do offer flexibility, but that flexibility should happen within a medically supervised framework, not based on how you're feeling about your bowel movements this week. If you're not sure whether your dose increase schedule is clinically appropriate, ask your prescriber directly.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 5 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Victoza for weight loss: what liraglutide actually does, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Victoza for weight loss: what liraglutide actually does should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator appears to be using Saxenda (liraglutide 3.
FormBlends verdict
The creator appears to be using Saxenda (liraglutide 3.0 mg, approved for weight management) but refers to it throughout as Victoza, which is a different liraglutide product approved only for type 2 diabetes at a maximum 1.8 mg dose. She is self-directing her titration from 2.4 mg to 3.0 mg with physician permission, which deviates from the standard weekly step-up schedule outlined in Saxenda's prescribing information. She also reports new injection site bruising at higher doses, a side effect that warrants technique review and prescriber consultation rather than peer input.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator appears to be using Saxenda (liraglutide 3.0 mg, approved for weight management) but refers to it throughout as Victoza, which is a different liraglutide product approved only for type 2 diabetes at a maximum 1.8 mg dose. She is self-directing her titration from 2.4 mg to 3.0 mg with physician permission, which deviates from the standard weekly step-up schedule outlined in Saxenda's prescribing information. She also reports new injection site bruising at higher doses, a side effect that warrants technique review and prescriber consultation rather than peer input.
- Victoza and Saxenda both contain liraglutide but are different products: Victoza is approved for type 2 diabetes at up to 1.8 mg, Saxenda for weight management at up to 3.0 mg. Using the wrong name matters for dosing expectations.
- Saxenda's prescribing information specifies a structured weekly titration (0.6 mg increments) to reduce GI side effects. Self-directed dose increases outside that schedule are not supported by FDA-approved guidelines.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Victoza and Saxenda both contain liraglutide but are different products: Victoza is approved for type 2 diabetes at up to 1.8 mg, Saxenda for weight management at up to 3.0 mg. Using the wrong name matters for dosing expectations.
- Saxenda's prescribing information specifies a structured weekly titration (0.6 mg increments) to reduce GI side effects. Self-directed dose increases outside that schedule are not supported by FDA-approved guidelines.
- Cortisol-driven weight gain under chronic stress is real and documented. Xenaki et al. (2022, Hormones) confirmed stress disrupts leptin, ghrelin, and fat distribution, particularly visceral fat in women.
- Injection site bruising is more often a technique issue than a dose issue. Standard guidance recommends rotating sites within approved zones and allowing alcohol to fully dry before injecting.
- Abdomen typically shows the most consistent liraglutide absorption. Thigh absorption is slightly more variable per Hofman et al. (2021, Diabetes Care), but the clinical difference is small for most patients.
- Addressing GI side effects like constipation before increasing dose is clinically sensible. Faster titration is directly associated with higher rates of nausea, vomiting, and constipation in liraglutide trials.
- Any concerns about injection site reactions, bruising, or dosing should go to your prescriber, not social media. Crowdsourced medical advice carries no accountability and often reflects individual variation, not generalizable guidance.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Rhonda Sigler · TikTok creator
11.8K views on this video
Where are my Victoza girlies? #victoza #weightloss #glp1 #liraglutide
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Rhonda Sigler, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.